m6A-centered Disease Response Information

General Information of the Disease (ID: M6ADIS0028)
Name
Thymoma
ICD
ICD-11: 2C27
Full List of Target Gene(s) of This m6A-centered Disease Response
Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)
 Target Info 
In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [1]
Response Summary This study highlighted METTL3 as a tumor promoter in Thymic tumors and c-MYC as a promising target to be exploited for the treatment of TET. High expression of c-MYC protein is enabled by lncRNA Metastasis associated lung adenocarcinoma transcript 1 (MALAT1), which is methylated and delocalized by METTL3. Silencing of METTL3 combined with cisplatin or c-MYC inhibitor induces cell death in TET cells. Blocking of c-MYC by using JQ1 inhibitor cooperates with METTL3 depletion in the inhibition of proliferation and induction of cell death.
Responsed Disease Thymic epithelial tumors [ICD-11: 2C27.Y]
Responsed Drug Cisplatin Approved
 Drug Info 
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Cellular senescence hsa04218
Cell Process Cell viability and proliferation
In-vitro Model T1889 Thymic undifferentiated carcinoma Homo sapiens CVCL_D024
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene [1]
Response Summary This study highlighted METTL3 as a tumor promoter in Thymic tumors and c-MYC as a promising target to be exploited for the treatment of TET. High expression of c-MYC protein is enabled by lncRNA Metastasis associated lung adenocarcinoma transcript 1 (MALAT1), which is methylated and delocalized by METTL3. Silencing of METTL3 combined with cisplatin or c-MYC inhibitor induces cell death in TET cells. Blocking of c-MYC by using JQ1 inhibitor cooperates with METTL3 depletion in the inhibition of proliferation and induction of cell death.
Responsed Disease Thymic epithelial tumors [ICD-11: 2C27.Y]
Responsed Drug JQ-1 Phase 1
 Drug Info 
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Cellular senescence hsa04218
Cell Process Cell viability and proliferation
In-vitro Model T1889 Thymic undifferentiated carcinoma Homo sapiens CVCL_D024
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
In total 2 item(s) under this disease
Crosstalk ID: M6ACROT05515
 Crosstalk Info 
m6A Regulator Methyltransferase-like 3 (METTL3)
 Regulator Info 
m6A Target Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)
 Target Gene 
Epigenetic Regulator Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)
Regulated Target Myc proto-oncogene protein (MYC)
Crosstalk relationship m6A → ncRNA
Drug JQ1
 Drug Info 
Crosstalk ID: M6ACROT05516
 Crosstalk Info 
m6A Regulator Methyltransferase-like 3 (METTL3)
 Regulator Info 
m6A Target Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)
 Target Gene 
Epigenetic Regulator Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)
Regulated Target Myc proto-oncogene protein (MYC)
Crosstalk relationship m6A → ncRNA
Drug Cisplatin
 Drug Info 
References
Ref 1 METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors. Clin Epigenetics. 2021 Sep 16;13(1):173. doi: 10.1186/s13148-021-01159-6.